Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: From enzymology to structural models

Current Medicinal Chemistry

Volumn 18, Issue 19, 2011, Pages 2836-2847

  Crespan, E ^a   Zucca, E ^a   Maga, G ^a  

^a CNR   (Italy)

Author keywords

Cancer; Drug resistance; Molecular targeted therapy; Tyrosine kinase

Indexed keywords

BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; FLT3 LIGAND; GEFITINIB; IMATINIB; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; LAPATINIB; NERATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRAZOLONE DERIVATIVE; PYRIMIDINE DERIVATIVE; SUNITINIB; THIADIAZOLE DERIVATIVE;

ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYMOLOGY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES;

EID: 79959935268     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796150513     Document Type: Article

References (146)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S., The protein kinase complement of the human genome. Science 2002, 298(5600), 1912-34. (Pubitemid 35425239)
2. Hubbard, S. R.; Miller, W. T., Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 2007, 19(2), 117-23. (Pubitemid 46386407)
3. (a) Roskoski, R., Jr., Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004, 324(4), 1155-64; (Pubitemid 40292143)
4. (b) Nagar, B.; Hantschel, O.; Seeliger, M.; Davies, J. M.; Weis, W. I.; Superti-Furga, G.; Kuriyan, J., Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 2006, 21(6), 787-98. (Pubitemid 43376129)
5. (a) Muller-Tidow, C.; Schwable, J.; Steffen, B.; Tidow, N.; Brandt, B.; Becker, K.; Schulze-Bahr, E.; Halfter, H.; Vogt, U.; Metzger, R.; Schneider, P. M.; Buchner, T.; Brandts, C.; Berdel, W. E.; Serve, H., High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res 2004, 10(4), 1241-9; (Pubitemid 38365213)
6. (b) Kanda, S.; Miyata, Y.; Kanetake, H.; Smithgall, T. E., Nonreceptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med 2007, 20(1), 113-21.
7. Colicelli, J., ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 2010, 3(139), re6.
8. Deininger, M. W.; Goldman, J. M.; Melo, J. V., The molecular biology of chronic myeloid leukemia. Blood 2000, 96(10), 3343-56.
9. Carroll, W. L.; Bhojwani, D.; Min, D. J.; Raetz, E.; Relling, M.; Davies, S.; Downing, J. R.; Willman, C. L.; Reed, J. C., Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003, 102-31.
10. Faderl, S.; Kantarjian, H. M.; Talpaz, M.; Estrov, Z., Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998, 91(11), 3995-4019. (Pubitemid 28261960)
11. (a) Graux, C.; Cools, J.; Melotte, C.; Quentmeier, H.; Ferrando, A.; Levine, R.; Vermeesch, J. R.; Stul, M.; Dutta, B.; Boeckx, N.; Bosly, A.; Heimann, P.; Uyttebroeck, A.; Mentens, N.; Somers, R.; MacLeod, R. A.; Drexler, H. G.; Look, A. T.; Gilliland, D. G.; Michaux, L.; Vandenberghe, P.; Wlodarska, I.; Marynen, P.; Hagemeijer, A., Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36(10), 1084-9; (Pubitemid 41184470)
12. (b) De Keersmaecker, K.; Graux, C.; Odero, M. D.; Mentens, N.; Somers, R.; Maertens, J.; Wlodarska, I.; Vandenberghe, P.; Hagemeijer, A.; Marynen, P.; Cools, J., Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t (9;14) (q34;q32). Blood 2005, 105(12), 4849-52; (Pubitemid 40807313)
13. (c) Zuna, J.; Zaliova, M.; Muzikova, K.; Meyer, C.; Lizcova, L.; Zemanova, Z.; Brezinova, J.; Votava, F.; Marschalek, R.; Stary, J.; Trka, J., Acute leukemias with ETV6/ABL1(TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer 2010, 49(10), 873-84.
14. Iijima, Y.; Ito, T.; Oikawa, T.; Eguchi, M.; Eguchi-Ishimae, M.; Kamada, N.; Kishi, K.; Asano, S.; Sakaki, Y.; Sato, Y., A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t (1;12) (q25;p13) translocation. Blood 2000, 95(6), 2126-31. (Pubitemid 30151655)
15. Van Etten, R. A., c-Abl regulation: a tail of two lipids. Curr Biol 2003, 13(15), R608-10. (Pubitemid 36953295)
16. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J., Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289(5486), 1938-42.
17. Gambacorti-Passerini, C.; Le Coutre, P.; Mologni, L.; Fanelli, M.; Bertazzoli, C.; Marchesi, E.; Di Nicola, M.; Biondi, A.; Corneo, G. M.; Belotti, D.; Pogliani, E.; Lydon, N. B., Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23(3), 380-94. (Pubitemid 28123720)
18. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23), 2408-17. (Pubitemid 44903745)
19. Gambacorti-Passerini, C. B.; Rossi, F.; Verga, M.; Ruchatz, H.; Gunby, R.; Frapolli, R.; Zucchetti, M.; Scapozza, L.; Bungaro, S.; Tornaghi, L.; Pioltelli, P.; Pogliani, E.; D'Incalci, M.; Corneo, G., Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. Blood Cells Mol Dis 2002, 28(3), 361-72. (Pubitemid 35216400)
20. (a) Weisberg, E.; Griffin, J. D., Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000, 95(11), 3498-505; (Pubitemid 30428483)
21. (b) Mahon, F. X.; Deininger, M. W.; Schultheis, B.; Chabrol, J.; Reiffers, J.; Goldman, J. M.; Melo, J. V., Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96(3), 1070-9. (Pubitemid 30616875)
22. (a) Apperley, J. F., Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8(12), 1116-28; (Pubitemid 350182968)
23. (b) Soverini, S.; Colarossi, S.; Gnani, A.; Rosti, G.; Castagnetti, F.; Poerio, A.; Iacobucci, I.; Amabile, M.; Abruzzese, E.; Orlandi, E.; Radaelli, F.; Ciccone, F.; Tiribelli, M.; di Lorenzo, R.; Caracciolo, C.; Izzo, B.; Pane, F.; Saglio, G.; Baccarani, M.; Martinelli, G., Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12(24), 7374-9; (Pubitemid 46095411)
24. (c) Deininger, M. W.; Cortes, J.; Paquette, R.; Park, B.; Hochhaus, A.; Baccarani, M.; Stone, R.; Fischer, T.; Kantarjian, H.; Niederwieser, D.; Gambacorti-Passerini, C.; So, C.; Gathmann, I.; Goldman, J. M.; Smith, D.; Druker, B. J.; Guilhot, F., The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 2007, 110(7), 1509-19. (Pubitemid 47463065)
25. Apperley, J. F., Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007, 8(11), 1018-29. (Pubitemid 47629897)
26. Roche-Lestienne, C.; Soenen-Cornu, V.; Grardel-Duflos, N.; Lai, J. L.; Philippe, N.; Facon, T.; Fenaux, P.; Preudhomme, C., Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100(3), 1014-8. (Pubitemid 34832631)
27. Griswold, I. J.; MacPartlin, M.; Bumm, T.; Goss, V. L.; O'Hare, T.; Lee, K. A.; Corbin, A. S.; Stoffregen, E. P.; Smith, C.; Johnson, K.; Moseson, E. M.; Wood, L. J.; Polakiewicz, R. D.; Druker, B. J.; Deininger, M. W., Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006, 26(16), 6082-93. (Pubitemid 44204527)
28. (a) Branford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Herrmann, R.; Seymour, J. F.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T., Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the AT P phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102(1), 276-83; (Pubitemid 36759665)
29. (b) Cang, S.; Liu, D., P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008, 1, 15;
30. (c) Branford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K. P.; Hughes, T. P., High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99(9), 3472-5; (Pubitemid 34525335)
31. (d) Sawyers, C. L., Research on resistance to cancer drug Gleevec. Science 2001, 294(5548), 1834. (Pubitemid 33101560)
32. (a) Jones, D.; Kamel-Reid, S.; Bahler, D.; Dong, H.; Elenitoba-Johnson, K.; Press, R.; Quigley, N.; Rothberg, P.; Sabath, D.; Viswanatha, D.; Weck, K.; Zehnder, J., Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn 2009, 11(1), 4-11;
33. (b) La Rosee, P.; Corbin, A. S.; Stoffregen, E. P.; Deininger, M. W.; Druker, B. J., Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002, 62(24), 7149-53. (Pubitemid 36025227)
34. Nam, H. J.; Haser, W. G.; Roberts, T. M.; Frederick, C. A., Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism. Structure 1996, 4(9), 1105-14. (Pubitemid 26369775)
35. Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, D. W.; Muller, M. C.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Kim, D.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A., Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27(25), 4204-10.
36. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2), 129-41. (Pubitemid 40248339)
37. Ray, A.; Cowan-Jacob, S. W.; Manley, P. W.; Mestan, J.; Griffin, J. D., Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107(nilotinib) by a random mutagenesis study. Blood 2007, 109(11), 5011-5. (Pubitemid 46827801)
38. Redaelli, S.; Piazza, R.; Rostagno, R.; Magistroni, V.; Perini, P.; Marega, M.; Gambacorti-Passerini, C.; Boschelli, F., Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27(3), 469-71.
39. Olivieri, A.; Manzione, L., Dasatinib: a new step in molecular target therapy. Ann Oncol 2007, 18 Suppl 6, vi42-6.
40. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E., The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006, 66(11), 5790-7. (Pubitemid 43927133)
41. (a) Hayette, S.; Chabane, K.; Michallet, M.; Michallat, E.; Cony-Makhoul, P.; Salesse, S.; Maguer-Satta, V.; Magaud, J. P.; Nicolini, F. E., Longitudinal studies of SRC family kinases in imatinib-and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res 2010;
42. (b) Soverini, S.; Martinelli, G.; Colarossi, S.; Gnani, A.; Rondoni, M.; Castagnetti, F.; Paolini, S.; Rosti, G.; Baccarani, M., Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 2007, 8(3), 273-4. (Pubitemid 46291717)
43. (a) Golas, J. M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, F.; Boschelli, D. H.; Boschelli, F., SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63(2), 375-81; (Pubitemid 36152495)
44. (b) Puttini, M.; Coluccia, A. M.; Boschelli, F.; Cleris, L.; Marchesi, E.; Donella-Deana, A.; Ahmed, S.; Redaelli, S.; Piazza, R.; Magistroni, V.; Andreoni, F.; Scapozza, L.; Formelli, F.; Gambacorti-Passerini, C., In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006, 66(23), 11314-22. (Pubitemid 46009962)
45. Kantarjian, H.; Le Coutre, P.; Cortes, J.; Pinilla-Ibarz, J.; Nagler, A.; Hochhaus, A.; Kimura, S.; Ottmann, O., Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010, 116(11), 2665-72.
46. Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C., Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer 2010, 46(10), 1781-9.
47. Crespan, E.; Radi, M.; Zanoli, S.; Schenone, S.; Botta, M.; Maga, G., Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinibresistant mutant with different mechanisms. Bioorg Med Chem 2010, 18(11), 3999-4008.
48. (a) Pecquet, C.; Nyga, R.; Penard-Lacronique, V.; Smithgall, T. E.; Murakami, H.; Regnier, A.; Lassoued, K.; Gouilleux, F., The Src tyrosine kinase Hck is required for Tel-Abl-but not for Tel-Jak2-induced cell transformation. Oncogene 2007, 26(11), 1577-85; (Pubitemid 46398735)
49. (b) Pene-Dumitrescu, T.; Peterson, L. F.; Donato, N. J.; Smithgall, T. E., An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 2008, 27(56), 7055-69.
50. Heinrich, M. C.; Griffith, D. J.; Druker, B. J.; Wait, C. L.; Ott, K. A.; Zigler, A. J., Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96(3), 925-32. (Pubitemid 30618049)
51. Duensing, A.; Medeiros, F.; McConarty, B.; Joseph, N. E.; Panigrahy, D.; Singer, S.; Fletcher, C. D.; Demetri, G. D.; Fletcher, J. A., Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004, 23(22), 3999-4006. (Pubitemid 38747928)
52. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B. C.; Wilson, K. P., Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004, 279(30), 31655-63. (Pubitemid 39037836)
53. Heinrich, M. C.; Corless, C. L.; Blanke, C. D.; Demetri, G. D.; Joensuu, H.; Roberts, P. J.; Eisenberg, B. L.; von Mehren, M.; Fletcher, C. D.; Sandau, K.; McDougall, K.; Ou, W. B.; Chen, C. J.; Fletcher, J. A., Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24(29), 4764-74. (Pubitemid 46630941)
54. Prenen, H.; Cools, J.; Mentens, N.; Folens, C.; Sciot, R.; Schoffski, P.; Van Oosterom, A.; Marynen, P.; Debiec-Rychter, M., Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006, 12(8), 2622-7.
55. Gan, H. K.; Seruga, B.; Knox, J. J., Sunitinib in solid tumors. Expert Opin Investig Drugs 2009, 18(6), 821-34.
56. Guo, T.; Hajdu, M.; Agaram, N. P.; Shinoda, H.; Veach, D.; Clarkson, B. D.; Maki, R. G.; Singer, S.; Dematteo, R. P.; Besmer, P.; Antonescu, C. R., Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009, 15(22), 6862-70.
57. Herbst, R. S., Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004, 59(2 Suppl), 21-6. (Pubitemid 38610223)
58. (a) Yang, C. H.; Yu, C. J.; Shih, J. Y.; Chang, Y. C.; Hu, F. C.; Tsai, M. C.; Chen, K. Y.; Lin, Z. Z.; Huang, C. J.; Shun, C. T.; Huang, C. L.; Bean, J.; Cheng, A. L.; Pao, W.; Yang, P. C., Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive nonsmall-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26(16), 2745-53;
59. (b) Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.; Provencio, M.; Insa, A.; Massuti, B.; Gonzalez-Larriba, J. L.; Paz-Ares, L.; Bover, I.; Garcia-Campelo, R.; Moreno, M. A.; Catot, S.; Rolfo, C.; Reguart, N.; Palmero, R.; Sanchez, J. M.; Bastus, R.; Mayo, C.; Bertran-Alamillo, J.; Molina, M. A.; Sanchez, J. J.; Taron, M., Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10), 958-67.
60. Johnson, L. N., Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009, 42(1), 1-40.
61. (a) Wu, J. Y.; Wu, S. G.; Yang, C. H.; Chang, Y. L.; Chang, Y. C.; Hsu, Y. C.; Shih, J. Y.; Yang, P. C., Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 2010;
62. (b) Riely, G. J.; Politi, K. A.; Miller, V. A.; Pao, W., Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12(24), 7232-41; (Pubitemid 46095394)
63. (c) Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3), e73.
64. Janne, P. A., Challenges of detecting EGFR T790M in gefitinib/ erlotinibresistant tumours. Lung Cancer 2008, 60 Suppl 2, S3-9. (Pubitemid 351726031)
65. Ruppert, A. M.; Beau-Faller, M.; Neuville, A.; Guerin, E.; Voegeli, A. C.; Mennecier, B.; Legrain, M.; Molard, A.; Jeung, M. Y.; Gaub, M. P.; Oudet, P.; Quoix, E., EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 2009, 33(2), 436-40.
66. Engelman, J. A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J. O.; Lindeman, N.; Gale, C. M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A. J.; Rogers, A. M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B. E.; Cantley, L. C.; Janne, P. A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827), 1039-43. (Pubitemid 46799492)
67. McDermott, U.; Pusapati, R. V.; Christensen, J. G.; Gray, N. S.; Settleman, J., Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010, 70(4), 1625-34.
68. Olayioye, M. A., Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of HER-2/HER-2 and family members. Breast Cancer Res 2001, 3(6), 385-9. (Pubitemid 34196365)
69. (a) Medina, P. J.; Goodin, S., Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008, 30(8), 1426-47;
70. (b) Hynes, N. E.; Schlange, T., Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 2006, 10(1), 7-11.
71. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L., A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64(18), 6652-9. (Pubitemid 39297926)
72. Liu, L.; Greger, J.; Shi, H.; Liu, Y.; Greshock, J.; Annan, R.; Halsey, W.; Sathe, G. M.; Martin, A. M.; Gilmer, T. M., Novel mechanism of lapatinib resistance in HER-2-positive breast tumor cells: activation of AXL. Cancer Res 2009, 69(17), 6871-8.
73. Trowe, T.; Boukouvala, S.; Calkins, K.; Cutler, R. E., Jr.; Fong, R.; Funke, R.; Gendreau, S. B.; Kim, Y. D.; Miller, N.; Woolfrey, J. R.; Vysotskaia, V.; Yang, J. P.; Gerritsen, M. E.; Matthews, D. J.; Lamb, P.; Heuer, T. S., EXEL-7647 inhibits mutant forms of HER-2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 2008, 14(8), 2465-75. (Pubitemid 351551082)
74. Parcells, B. W.; Ikeda, A. K.; Simms-Waldrip, T.; Moore, T. B.; Sakamoto, K. M., FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 2006, 24(5), 1174-84. (Pubitemid 44464685)
75. Markovic, A.; MacKenzie, K. L.; Lock, R. B., FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 2005, 37(6), 1168-72. (Pubitemid 40381193)
76. Vainchenker, W.; Dusa, A.; Constantinescu, S. N., JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008, 19(4), 385-93.
77. Pesu, M.; Laurence, A.; Kishore, N.; Zwillich, S. H.; Chan, G.; O'Shea, J. J., Therapeutic targeting of Janus kinases. Immunol Rev 2008, 223, 132-42. (Pubitemid 351986189)
78. Wang, H.; Gambosova, K.; Cooper, Z. A.; Holloway, M. P.; Kassai, A.; Izquierdo, D.; Cleveland, K.; Boney, C. M.; Altura, R. A., EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic beta-cells. BMC Mol Biol 2010, 11, 66.
79. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R. A., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773(8), 1263-84. (Pubitemid 47125967)
80. Pang, R. W.; Poon, R. T., Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag 2006, 2(2), 97-108. (Pubitemid 43853426)
81. Achen, M. G.; Stacker, S. A., Molecular control of lymphatic metastasis. Ann N Y Acad Sci 2008, 1131, 225-34. (Pubitemid 351758517)
82. Eichhorn, M. E.; Kleespies, A.; Angele, M. K.; Jauch, K. W.; Bruns, C. J., Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007, 392(3), 371-9. (Pubitemid 46675800)
83. Friedberg, J. W.; Sharman, J.; Sweetenham, J.; Johnston, P. B.; Vose, J. M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J. P.; Cripe, L. D.; Gregory, S. A.; Sterba, M. P.; Lowe, A. M.; Levy, R.; Shipp, M. A., Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13), 2578-85.
84. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107(29), 13075-80.
85. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H., Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007, 448(7153), 561-6. (Pubitemid 47206930)
86. Amin, H. M.; Lai, R., Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007, 110(7), 2259-67. (Pubitemid 47523143)
87. Santos, F. P.; Kantarjian, H. M.; Jain, N.; Manshouri, T.; Thomas, D. A.; Garcia-Manero, G.; Kennedy, D.; Estrov, Z.; Cortes, J.; Verstovsek, S., Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115(6), 1131-6.
88. Rabasseda, X., Marching against blood diseases: a report from the 51st Annual Meeting of the American Society of Hematology (December 5-8, 2009 - New Orleans, Lousiana, USA). Drugs Today (Barc) 2010, 46(3), 195-230.
89. Hitoshi, Y.; Lin, N.; Payan, D. G.; Markovtsov, V., The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol 2010, 91(2), 189-200.
90. Quintas-Cardama, A.; Vaddi, K.; Liu, P.; Manshouri, T.; Li, J.; Scherle, P. A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.; Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers, J. D.; Haley, P.; Kantarjian, H.; Fridman, J. S.; Verstovsek, S., Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115(15), 3109-17.
91. Shilling, A. D.; Nedza, F. M.; Emm, T.; Diamond, S.; McKeever, E.; Punwani, N.; Williams, W.; Arvanitis, A.; Galya, L. G.; Li, M.; Shepard, S.; Rodgers, J.; Yue, T. Y.; Yeleswaram, S., Metabolism, Excretion and Pharmacokinetics of 14C-INCB018424, a Selective JAK1/2 Inhibitor, in Humans. Drug Metab Dispos 2010.
92. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C., Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006, 108(12), 3674-81. (Pubitemid 44864544)
93. Kojima, K.; Konopleva, M.; Tsao, T.; Andreeff, M.; Ishida, H.; Shiotsu, Y.; Jin, L.; Tabe, Y.; Nakakuma, H., Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia 2010, 24(1), 33-43.
94. Geyer, J. R.; Stewart, C. F.; Kocak, M.; Broniscer, A.; Phillips, P.; Douglas, J. G.; Blaney, S. M.; Packer, R. J.; Gururangan, S.; Banerjee, A.; Kieran, M. W.; Kun, L. E.; Gilbertson, R. J.; Boyett, J. M., A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer 2010.
95. Yin, Y. M.; Geng, Y. T.; Shao, Y. F.; Hu, X. L.; Li, W.; Shu, Y. Q.; Wang, Z. X., First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. J Exp Clin Cancer Res 2010, 29, 126.
96. Kumar, A.; Petri, E. T.; Halmos, B.; Boggon, T. J., Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008, 26(10), 1742-51.
97. Perez-Soler, R., Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 2004, 6 Suppl 1, S20-3.
98. Xu, X. H.; Su, J.; Fu, X. Y.; Xue, F.; Huang, Q.; Li, D. J.; Lu, M. Q., Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2010.
99. Reck, M.; van Zandwijk, N.; Gridelli, C.; Baliko, Z.; Rischin, D.; Allan, S.; Krzakowski, M.; Heigener, D., Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010, 5(10), 1616-22.
100. Hirte, H.; Oza, A.; Swenerton, K.; Ellard, S. L.; Grimshaw, R.; Fisher, B.; Tsao, M.; Seymour, L., A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol 2010, 118(3), 308-12.
101. Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C. G.; Chan, S.; Jagiello-Gruszfeld, A.; Kaufman, B.; Crown, J.; Chan, A.; Campone, M.; Viens, P.; Davidson, N.; Gorbounova, V.; Raats, J. I.; Skarlos, D.; Newstat, B.; Roychowdhury, D.; Paoletti, P.; Oliva, C.; Rubin, S.; Stein, S.; Geyer, C. E., A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112(3), 533-43.
102. Cameron, D.; Casey, M.; Oliva, C.; Newstat, B.; Imwalle, B.; Geyer, C. E., Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010, 15(9), 924-34.
103. Diaz, R.; Nguewa, P. A.; Parrondo, R.; Perez-Stable, C.; Manrique, I.; Redrado, M.; Catena, R.; Collantes, M.; Penuelas, I.; Diaz-Gonzalez, J. A.; Calvo, A., Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 2010, 10, 188.
104. Rocha-Lima, C. M.; Soares, H. P.; Raez, L. E.; Singal, R., EGFR targeting of solid tumors. Cancer Control 2007, 14(3), 295-304. (Pubitemid 47057800)
105. Cortes-Funes, H.; Mendiola, C.; Manso, L.; Ciruelos, E., Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER-2+ breast cancer. Breast Cancer Res 2009, 11 Suppl 1, S19.
106. Ho, Q. T.; Kuo, C. J., Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007, 39(7-8), 1349-57. (Pubitemid 47031045)
107. Oudard, S.; George, D.; Medioni, J.; Motzer, R., Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 2007, 18 Suppl 10, x25-31.
108. Larkin, J. M.; Eisen, T., Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006, 60(3), 216-26. (Pubitemid 44709619)
109. Joensuu, H., Sunitinib for imatinib-resistant GIST. Lancet 2006, 368(9544), 1303-4. (Pubitemid 44550131)
110. Gore, M. E.; Hariharan, S.; Porta, C.; Bracarda, S.; Hawkins, R.; Bjarnason, G. A.; Oudard, S.; Lee, S. H.; Carteni, G.; Nieto, A.; Yuan, J.; Szczylik, C., Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2010.
111. Younus, J.; Verma, S.; Franek, J.; Coakley, N., Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 2010, 17(4), 4-10.
112. Huynh, H., Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010, 80(5), 550-60.
113. Eder, J. P.; Shapiro, G. I.; Appleman, L. J.; Zhu, A. X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L.; McCallum, S.; Heath, E. I.; Boerner, S. A.; LoRusso, P. M., A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010, 16(13), 3507-16.
114. Mekhail, T.; Masson, E.; Fischer, B.; Gong, J.; Iyer, R.; Gan, J.; Pursley, J.; Patricia, D.; Williams, D.; Ganapathi, R., Metabolism, Excretion, and Pharmacokinetics of Oral Brivanib in Patients with Advanced or Metastatic Solid Tumors. Drug Metab Dispos 2010.
115. van Cruijsen, H.; van der Veldt, A.; Hoekman, K., Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci 2009, 14, 2248-68.
116. Lorusso, P.; Shields, A. F.; Gadgeel, S.; Vaishampayan, U.; Guthrie, T.; Puchalski, T.; Xu, J.; Liu, Q., Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs 2010.
117. Schiller, J. H.; Larson, T.; Ou, S. H.; Limentani, S.; Sandler, A.; Vokes, E.; Kim, S.; Liau, K.; Bycott, P.; Olszanski, A. J.; von Pawel, J., Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009, 27(23), 3836-41.
118. Rini, B. I.; Wilding, G.; Hudes, G.; Stadler, W. M.; Kim, S.; Tarazi, J.; Rosbrook, B.; Trask, P. C.; Wood, L.; Dutcher, J. P., Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27(27), 4462-8.
119. Zhang, Y.; Guessous, F.; Kofman, A.; Schiff, D.; Abounader, R., XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010, 13(2), 112-21.
120. Konings, I. R.; de Jonge, M. J.; Burger, H.; van der Gaast, A.; van Beijsterveldt, L. E.; Winkler, H.; Verweij, J.; Yuan, Z.; Hellemans, P.; Eskens, F. A., Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer 2010, 103(7), 987-92.
121. Flanigan, J.; Deshpande, H.; Gettinger, S., Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 2010, 4, 237-43.
122. Robinson, B. G.; Paz-Ares, L.; Krebs, A.; Vasselli, J.; Haddad, R., Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95(6), 2664-71.
123. Kim, C.; Lee, J. L.; Choi, Y. H.; Kang, B. W.; Ryu, M. H.; Chang, H. M.; Kim, T. W.; Kang, Y. K., Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2010.
124. Garcia, J. A.; Hutson, T. E.; Elson, P.; Cowey, C. L.; Gilligan, T.; Nemec, C.; Dreicer, R.; Bukowski, R. M.; Rini, B. I., Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer 2010.
125. Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schoffski, P.; Collin, F.; Pandite, L.; Marreaud, S.; De Brauwer, A.; van Glabbeke, M.; Verweij, J.; Blay, J. Y., Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancersoft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009, 27(19), 3126-32.
126. Friedlander, M.; Hancock, K. C.; Rischin, D.; Messing, M. J.; Stringer, C. A.; Matthys, G. M.; Ma, B.; Hodge, J. P.; Lager, J. J., A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119(1), 32-7.
127. Calabro, F.; Sternberg, C. N., Novel Targeted therapy for advanced renal carcinoma: trials in progress. Curr Opin Urol 2010, 20(5), 382-7.
128. Eskens, F. A.; Steeghs, N.; Verweij, J.; Bloem, J. L.; Christensen, O.; van Doorn, L.; Ouwerkerk, J.; de Jonge, M. J.; Nortier, J. W.; Kraetzschmar, J.; Rajagopalan, P.; Gelderblom, H., Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 2009, 27(25), 4169-76.
129. Langenberg, M. H.; Witteveen, P. O.; Roodhart, J. M.; Verheul, H. M.; Mergui-Roelvink, M.; van der Sar, J.; Brendel, E.; Laferriere, N.; Schellens, J. H.; Voest, E. E., Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2010, 16(7), 2187-97.
130. Benjamin, R. S.; Schoffski, P.; Hartmann, J. T.; Van Oosterom, A.; Bui, B. N.; Duyster, J.; Schuetze, S.; Blay, J. Y.; Reichardt, P.; Rosen, L. S.; Skubitz, K.; McCoy, S.; Sun, Y. N.; Stepan, D. E.; Baker, L., Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2010.
131. Sawaki, A.; Yamada, Y.; Komatsu, Y.; Kanda, T.; Doi, T.; Koseki, M.; Baba, H.; Sun, Y. N.; Murakami, K.; Nishida, T., Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. Cancer Chemother Pharmacol 2010, 65(5), 961-7.
132. Lu, J. F.; Claret, L.; Sutjandra, L.; Kuchimanchi, M.; Melara, R.; Bruno, R.; Sun, Y. N., Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol 2010.
133. Schlumberger, M. J.; Elisei, R.; Bastholt, L.; Wirth, L. J.; Martins, R. G.; Locati, L. D.; Jarzab, B.; Pacini, F.; Daumerie, C.; Droz, J. P.; Eschenberg, M. J.; Sun, Y. N.; Juan, T.; Stepan, D. E.; Sherman, S. I., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27(23), 3794-801.
134. Blumenschein, G. R., Jr.; Reckamp, K.; Stephenson, G. J.; O'Rourke, T.; Gladish, G.; McGreivy, J.; Sun, Y. N.; Ye, Y.; Parson, M.; Sandler, A., Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 2010, 16(1), 279-90.
135. Murakami, H.; Ueda, Y.; Shimoyama, T.; Yamamoto, N.; Yamada, Y.; Arioka, H.; Tamura, T., Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer Chemother Pharmacol 2010.
136. Ueda, Y.; Shimoyama, T.; Murakami, H.; Yamamoto, N.; Yamada, Y.; Arioka, H.; Tamura, T., Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010.
137. Kanai, F.; Yoshida, H.; Tateishi, R.; Sato, S.; Kawabe, T.; Obi, S.; Kondo, Y.; Taniguchi, M.; Tagawa, K.; Ikeda, M.; Morizane, C.; Okusaka, T.; Arioka, H.; Shiina, S.; Omata, M., A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010.
138. Lee, S. H.; Lopes de Menezes, D.; Vora, J.; Harris, A.; Ye, H.; Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S. L.; Gelb, A. B.; Heise, C., In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005, 11(10), 3633-41. (Pubitemid 40685578)
139. Wong, C. I.; Koh, T. S.; Soo, R.; Hartono, S.; Thng, C. H.; McKeegan, E.; Yong, W. P.; Chen, C. S.; Lee, S. C.; Wong, J.; Lim, R.; Sukri, N.; Lim, S. E.; Ong, A. B.; Steinberg, J.; Gupta, N.; Pradhan, R.; Humerickhouse, R.; Goh, B. C., Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009, 27(28), 4718-26.
140. Cook, N.; Basu, B.; Biswas, S.; Kareclas, P.; Mann, C.; Palmer, C.; Thomas, A.; Nicholson, S.; Morgan, B.; Lomas, D.; Sirohi, B.; Mander, A. P.; Middleton, M.; Corrie, P. G., A phase 2 study of vatalanib in metastatic melanoma patients. Eur J Cancer 2010, 46(15), 2671-3.
141. Mross, K.; Stefanic, M.; Gmehling, D.; Frost, A.; Baas, F.; Unger, C.; Strecker, R.; Henning, J.; Gaschler-Markefski, B.; Stopfer, P.; de Rossi, L.; Kaiser, R., Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010, 16(1), 311-9.
142. Ellis, P. M.; Kaiser, R.; Zhao, Y.; Stopfer, P.; Gyorffy, S.; Hanna, N., Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010, 16(10), 2881-9.
143. Baselga, J.; Cervantes, A.; Martinelli, E.; Chirivella, I.; Hoekman, K.; Hurwitz, H. I.; Jodrell, D. I.; Hamberg, P.; Casado, E.; Elvin, P.; Swaisland, A.; Iacona, R.; Tabernero, J., Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 2010, 16(19), 4876-83.
144. Morrow, C. J.; Ghattas, M.; Smith, C.; Bonisch, H.; Bryce, R. A.; Hickinson, D. M.; Green, T. P.; Dive, C., Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Cancer Res 2010, 70(14), 5931-41.
145. Lara, P. N., Jr.; Longmate, J.; Evans, C. P.; Quinn, D. I.; Twardowski, P.; Chatta, G.; Posadas, E.; Stadler, W.; Gandara, D. R., A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009, 20(3), 179-84.
146. Neal, J. W.; Sequist, L. V., Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010, 11(1-2), 36-44.